Crossmark

Authors

Gupta, Medhavi https://orcid.org/0000-0002-5780-5526

Akhtar, Othman Salim

Bahl, Bhavyaa

Mier-Hicks, Angel

Attwood, Kristopher

Catalfamo, Kayla

Gyawali, Bishal https://orcid.org/0000-0001-7444-8594

Torka, Pallawi

Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01968213 at ClinicalTrials.gov

Documents that mention this clinical trial

Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age
https://doi.org/10.1136/ijgc-2019-esgo.29

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288

Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review
https://doi.org/10.1136/ijgc-2019-001041

O016/#233 Clinical and molecular characteristics of ariel3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC)
https://doi.org/10.1136/ijgc-2021-igcs.16

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
https://doi.org/10.1136/ijgc-2020-002240

The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers
https://doi.org/10.1136/ijgc-2020-001789

Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499

Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
https://doi.org/10.1016/j.ygyno.2015.03.042

Health-related quality of life outcomes reporting associated with FDA approvals in haematology and oncology
https://doi.org/10.1136/bmjonc-2024-000369

Targeting the hallmarks of ovarian cancer: The big picture
https://doi.org/10.1016/j.ygyno.2016.03.037

Homologous recombination deficiency and ovarian cancer
https://doi.org/10.1016/j.ejca.2016.03.005

O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
https://doi.org/10.1136/ijgc-2022-igcs.5

3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations
https://doi.org/10.1136/ijgc-2020-igcs.3

PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials
https://doi.org/10.1016/j.ygyno.2016.05.003

1 Analysis of patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer in the phase 3 ARIEL3 study
https://doi.org/10.1136/ijgc-2021-esgo.331

Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
https://doi.org/10.1136/ijgc-2022-003614

Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know
https://doi.org/10.1016/j.ygyno.2016.01.003

2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
https://doi.org/10.1136/ijgc-2022-esgo.488